Oct 13, 2026 —
Researchers have described a high-throughput analytical method that uses UV-derived light scattering to screen conditions for purifying adeno-associated virus-like particles (VLPs), a step that matters for anyone optimizing AAV manufacturing.
The method reads absorbance at two wavelengths at once, 320 nm to track particle scattering and 280 nm to follow soluble proteins, so a lab can evaluate hundreds of precipitation and aqueous two-phase separation conditions in days rather than relying on slower, capsid-specific assays. The proof of concept used VP3-only AAV5 VLPs produced in E. coli.
Faster process-development screening is a practical lever on AAV cost and timelines, an area of steady interest for gene therapy developers and their manufacturing partners.
